Abstract
Overview
Introduction
Datamonitor expects the antithrombotics market to peak at just over $20
billion in 2012, across the seven major markets. The growth will be driven by
the uptake of the novel oral anticoagulants - Bayer' s Xarelto and BI' s Rendix
- which are expected to launch simultaneously, in 2008.
Scope
- Event-driven sales forecasts for 2007-16 across the seven major markets:
US, France, Germany, Italy, Spain, UK and Japan.
- Country and market specific issues that will impact sales opportunities
and market landscape, including key patent expiries and product launches.
- Case studies assessing the possibility that a novel, oral anticoagulant
may replace warfarin; and detailing the Plavix patent dispute with Apotex.
- Analysis of the main antithrombotics drugs, with a qualitative assessment
of their future market potential, backed-up by thought-leader opinion.
Highlights
The antithrombotics market is mature, however, the possibility of engineering
a replacement for warfarin, or a side-effect free, oral anticoagulant suitable
for chronic anticoagulation does represent an attractive opportunity for R&D
expenditure. The simultaneous launch of FXa inhibitor Xarelto, and DTI,
Rendix, will occur in 2008.
Cost containment initiatives, promoting the prescription of generic drugs, are
being introduced across the seven major markets and will constrain growth.
However, a paradigm shift towards thrombosis prophylaxis, will expand the oral
anticoagulant markets in terms of stroke prevention in atrial fibrillation and
post-surgical patient populations.
Sanofi-Aventis' s Lovenox (enoxaparin) is the dominant LMWH, generating sales
of $3.0 billion in 2006 and thereby accounting for 72% of the overall heparin
market and 80% of the LMWH market. However, the Lovenox patent expires in 2012
and so Lovenox revenues will be subject to generic erosion over the forecast
period.
Reasons to Purchase
- Quantify the future size of the antithrombotics market and identify
opportunities for new products.
- Learn how the premature expiry of the Plavix patent would have shaped the
market and understand why Apotex chose to launch a generic "at risk".
- Understand the barriers to uptake that novel anticoagulants may experience
in attempting to replace warfarin.
| 
View Cart
